New Hampshire Bulletin2d
Health experts outline how Trump administration could affect abortion, contraception access
President-elect Donald Trump has several choices to make in the coming months about whether his second administration will ...
The American Journal of Managed Care2d
Sunvozertinib NDA Submitted to FDA for NSCLC
A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...
Targeted Oncology2d
Sunvozertinib New Drug Application in EGFR-Mutant NSCLC Submitted to FDA
Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...
JD Supra5d
New Momentum for a Time-Limited Conditional Approval Pathway for Rare Disease Drugs
On October 4, 2024, a US House version of the revised Promising Pathway Act (PPA) 2.0 was introduced, sponsored by Rep. Bruce Westerman (R-AR).